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Abstract
Myostatin, a negative regulator of muscle growth, has been implicated in sporadic inclusion body myositis (sIBM). sIBM is
the most common age-related muscle-wastage disease with a pathogenesis similar to that of amyloid disorders such as
Alzheimer’s and Parkinson’s diseases. Myostatin precursor protein (MstnPP) has been shown to associate with large
molecular weight filamentous inclusions containing the Alzheimer’s amyloid beta peptide in sIBM tissue, and MstnPP is
upregulated following ER stress. The mechanism for how MstnPP contributes to disease pathogenesis is unknown. Here, we
show for the first time that MstnPP is capable of forming amyloid fibrils in vitro. When MstnPP-containing Escherichia coli
inclusion bodies are refolded and purified, a proportion of MstnPP spontaneously misfolds into amyloid-like aggregates as
characterised by electron microscopy and binding of the amyloid-specific dye thioflavin T. When subjected to a slightly
acidic pH and elevated temperature, the aggregates form straight and unbranched amyloid fibrils 15 nm in diameter and
also exhibit higher order amyloid structures. Circular dichroism spectroscopy reveals that the amyloid fibrils are dominated
by b-sheet and that their formation occurs via a conformational change that occurs at a physiologically relevant
temperature. Importantly, MstnPP aggregates and protofibrils have a negative effect on the viability of myoblasts. These
novel results show that the myostatin precursor protein is capable of forming amyloid structures in vitro with implications
for a role in sIBM pathogenesis.
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Introduction
Myostatin is a member of the transforming growth factor-beta
(TGF-b) superfamily of growth and differentiation factors and is a
primary regulator of muscle growth both pre- and postnatally,
primarily via inhibition of myoblast proliferation and differentia-
tion [1–4]. Like other members of the family, myostatin is
translated as a precursor protein (MstnPP) that consists of an N-
terminal signal sequence, a regulatory propeptide domain (residues
21–266) and a growth factor domain (residues 267–374) which
dimerises at the C-terminus via an inter-molecular disulfide bond
[5–7]. The mature growth factor dimer is cleaved from the
propeptide region by furin convertase proteolysis in the endoplas-
mic reticulum (ER) at a conserved RSRR sequence [2,7]. The
propeptide region plays at least two important functions. First, as a
chaperone in the ER to assist in the folding of the growth factor
region [8,9] that contains the intricate cysteine-knot motif
characteristic of the family [10,11]. Second, the N-terminal
propeptide plays a regulatory role after cleavage, remaining non-
covalently associated with the mature dimer to form a latent
complex which is exported from the cell [7]. Myostatin remains
latent until a second cleavage event immediately N-terminal to
aspartate 76 of the propeptide region, most probably by
metalloproteinases, that disrupts the association [12,13]. It is
possible that furin cleavage of MstnPP also occurs post-secretion
with a pool of extracellular MstnPP identified in skeletal muscle
[14]. The mature growth factor dimer is structurally similar to
other members of the TGF-b family [11]; however the structural
characteristics of MstnPP or the propeptide region remain
undetermined.
Signalling by the myostatin growth factor via activin and TGF-
b receptors [2] ultimately results in cell-cycle arrest through the
upregulation of genes involved in cell-cycle withdrawal such as p21
and p53 and the downregulation of myogenic regulatory factors
such as MyoD and myogenin [15–18]. Although postnatally this
action maintains the quiescence of muscle satellite cells, the
prenatal role is more complex and depends on the environmental
context during development, with signalling by myostatin ensuring
that a balance between proliferation and differentiation is
maintained [19].
Myostatin-null mutations have been identified in dogs, cattle
and sheep, resulting in a double-muscled phenotype [1,20,21] and
an exceptionally muscular and strong human lacking functional
myostatin protein was also recently identified [22,23]. Myostatin
overexpression in mice induces profound muscle and fat loss
analogous to that seen in human cachexia syndromes [4] and
ectopically expressed myostatin rapidly lowers muscle mass in rats
[24]. Myostatin signalling can have negative consequences in a
diseased background such as the muscular dystrophies [25] and
may contribute to cachexia associated with many chronic disease
states [4] including HIV [26] and cancer [27]. For these reasons,
since its discovery in 1997 [3], the processed myostatin growth
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factor dimer has been suggested to hold exciting potential for
inhibitory targeting in a wide range of muscle wastage diseases
[28,29].
Less focus had been placed on the involvement of MstnPP or
the propeptide region in disease until a role for MstnPP in the
pathogenesis of sporadic inclusion body myositis (sIBM) was
proposed [30,31]. sIBM is the most common progressive muscle
wastage disease associated with aging where progressive muscle
loss leads to severe atrophy and weakness. Although the
pathogenesis is unknown, it is likely that oxidative damage
contributes to aging of the muscle fibers [30]. Endoplasmic
reticulum (ER) stress and the unfolded protein response (UPR)
have been demonstrated in sIBM muscle fibers [30,32]. Inflam-
mation and amyloid formation appear to be predominant features
but whether these are causally related and which is the primary
cause of sIBM, remain matters of debate [30,33]. The presence of
fibrillar inclusions in some diseased tissue suggests that sIBM may
be an amyloid disease, where a prominent feature is protein
aggregation and the subsequent formation and deposition of large
amyloid fibrils analogous to those observed for neurodegenerative
disorders such as Alzheimer’s, Parkinson’s and Huntington’s
diseases, the spongiform encephalopathies, the systemic amyloid-
oses and type II diabetes [34,35]. Despite extensive research, the
mechanisms behind amyloid formation and how they contribute to
disease remain poorly understood. It is well-documented that fibril
formation occurs via one or more oligomeric intermediate stages
[36–40] and it appears that an intermediate oligomeric species,
rather than the mature fibril, is the mediator of cyto- and
neurotoxicity [41–43]. Amyloid fibrils, characterised by extensive
b-sheet secondary structure, are deposited in tissues and are
resistant to degradation but may actually be chemically inert [35].
The filamentous inclusions of sIBM tissue contain a number of
molecules normally alien to muscle fibers, predominantly the
amyloid beta (Ab) protein of Alzheimer’s disease [44]. Biopsies from
sIBM muscle fibers revealed a close association of the myostatin
precursor protein (MstnPP) with Ab aggregates and increased levels
of both MstnPP and the processed myostatin growth factor dimer
[31]. Furthermore, when muscle cells are placed in conditions that
result in endoplasmic reticulum (ER) stress, MstnPP is upregulated
and an sIBM-like pathology is observed [45]. ER stress may lead to
the misfolding and aggregation of MstnPP. Cultured human muscle
fibers (CHMFs) overexpressing Ab precursor protein showed an
increase in MstnPP protein levels and subsequent experimental
inhibition of the proteasome caused co-accumulation of MstnPP
and AbPP/Ab within aggresomes [46]. CHMFs subjected to
tunicamycin or thapsigargin, compounds that inhibit protein
glycosylation and disrupt ER calcium levels respectively inducing
ER stress, also showed an increase in MstnPP expression (in
addition to ER stress marker proteins GRP78 and Herp), possibly
due to the activation of NF-kB [45]. In contrast to proteasome
inhibition, where MstnPP mRNA levels were decreased, NF-kB
activation increases transcription of MstnPP mRNA in a stressed
situation. These differences may be explained by the observation
that the nature and duration of ER stress may be important in
determining whether a cell activates a protective pathway or enters
apoptosis [47,48]. An additional mechanism for how myostatin/
MstnPP contributes to sIBM is focused on increased activity by the
myostatin growth factor. As myostatin is a procachectic growth
factor postnatally, increased production and processing of MstnPP
may result in increased levels of circulating myostatin growth factor
and signalling that leads to atrophy [45,46,49], though there is little
evidence supporting this hypothesis. A number of peptide
hormones, such as those in secretory granules of the endocrine
system, have been found to aggregate into amyloids in secretory
pathways in a regulated, functional manner [50,51], so there is a
possibility that myostatin aggregates are protective in the sIBM
diseased state.
The role of MstnPP in sIBM has not been firmly established.
Our research shows for the first time that MstnPP is able to form
amyloid fibrils independently in vitro via a pathway that produces
cytotoxic intermediates. When MstnPP is refolded and purified
from E. coli inclusion bodies, a population of MstnPP spontane-
ously misfolds into amyloid protofibril-like aggregates that can be
visualised using electron microscopy and bind the amyloid-specific
dye thioflavin T. When subjected to a slightly acidic pH and
elevated temperature, the protofibril-like aggregates form straight
and unbranched amyloid fibrils that are 15 nm in diameter and
exhibit higher order amyloid structures such as twists and bundles.
The fibrils are resistant to trypsin digest after incubation overnight
at 37uC. Circular dichroism spectroscopy reveals that MstnPP
undergoes a number of structural transitions through aggregation
to amyloid protofibril and fibril formation that initiate at a
physiologically relevant temperature. Significantly, MstnPP aggre-
gates and protofibrils have a negative effect on the viability of
C2C12 mouse myoblasts when added to the culture medium.
These results support a role for MstnPP in the pathogenesis of
sIBM and present the hypothesis that this role may be within a
degenerative context.
Results
MstnPP Is Predicted to Be Prone to Aggregation and
Disorder In Silico
In silico programs have been shown to accurately predict the
regions of a polypeptide chain that are prone to b-sheet
aggregation and amyloid formation. The MstnPP amino acid
sequence was analysed for b-aggregation propensity (Fig. 1A) using
Tango [52] (Fig. S1A) and PASTA [53,54] (Fig. S1B) and for
amyloidogenic regions using Waltz [55] (Fig. S1C). Both Tango
and PASTA predicted a high propensity for b-aggregation for
residues within the pro-peptide region, 154–177 (Fig. 1A); residues
139–153 were also predicted by PASTA to have b-aggregation
tendencies, albeit at a comparatively lower level. Tango also
identified growth factor domain sequences, 314–321 and 347–355.
Waltz predicted the same propeptide amyloidogenic regions,
153–162 and 168–177 as well as the very C-terminus of the
protein, 348–364. Mapping of aggregation-prone regions of the
myostatin growth factor onto the published crystal structure [11]
shows that residues 348–364 localise to the b-sheet ‘fingers’ of the
growth factor (Fig. 1B).
In Vitro Refolding of MstnPP Results in the Production of
Large Soluble Aggregates
Human MstnPP is found in inclusion bodies when overex-
pressed in E. coli like other TGF-b family members [56,57] and
can be refolded in vitro using a modification of methods described
for zebra-fish myostatin [8]. After refolding, in addition to the
native disulfide-bonded MstnPP dimer, two other species were
apparent by non-reducing SDS-PAGE; misfolded monomer and a
very high molecular weight species that has been characterised
previously as soluble aggregates [8,9] (Fig. 2A), which are
frequently observed during protein refolding [58]. Native MstnPP
was purified by heparin affinity chromatography that separated
the correctly folded MstnPP dimer from the majority of the
aggregates followed by the removal of remaining aggregates by gel
filtration. During heparin chromatography, the correctly folded
dimer eluted at 200 mM NaCl (H1) and the majority of aggregates
as a large peak at 600 mM NaCl (H2) (Fig. 2B and Fig. S2A).
Myostatin Amyloid Formation
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Western blotting identifies both peaks as myostatin (Fig. S2B) but
the two species interact differently with the heparin column
suggesting a difference in folding. Further purification of both
peaks was achieved using gel filtration (Fig. 2C). The aggregates
are too large to move from the well into an SDS-PAGE gel (above
250 kDa, Fig. 2A), elute in the void volume during S200 gel
filtration (PA) (Fig. 2C) and remain soluble even after ultracen-
trifugation at 214,0006g (data not shown). Since the MstnPP
monomer is 43 kDa the soluble aggregates are most likely to be an
oligomer of at least 5 monomeric units.
MstnPP Soluble Aggregates Have Characteristics of
Amyloid-Like Protofibrils
Transmission electron microscopy (TEM, Fig. 3A and B)
revealed that MstnPP soluble aggregates exhibit a morphology and
size similar to that documented for amyloid protofibrils from a
number of other proteins such as lysozyme [59,60] and HypF-N
[61] as well as the insulin protofibrils generated as a positive
control (Fig. 3C) using a well-established protocol [39,62,63]. A
range of structures, including spheres and oligomers of associated
spheres (diameter 15.661.6 nm SD), can be seen, and examples of
increased elongation of the aggregates are apparent (Fig. 3B).
A defining characteristic of amyloid fibrils and protofibrils is
their ability to bind the fluorescent dye thioflavin T (ThT) [63–65].
When bound to fibrils, ThT can be excited at 450 nm to fluoresce
at 485 nm [66]. One limitation of this method is the lack of a strict
quantitative relationship [64] with amyloid fibrils often producing
a stronger emission than protofibrils by comparison [65]. ThT
binding assays were carried out on the MstnPP aggregates and
compared to a solution containing a mixture of insulin protofibrils
and fibrils as a positive control. The MstnPP soluble aggregates
bound ThT with intensity comparable to insulin fibrils whereas
the correctly folded MstnPP dimer did not (Fig. 3D). These results
suggest that a population of MstnPP can aggregate spontaneously
to form amyloid-like protofibrils.
Formation of MstnPP Amyloid Fibrils at Acidic pH and
Elevated Temperature
The presence of MstnPP amyloid-like protofibrils suggests that
amyloid fibril formation is also possible. MstnPP aggregates were
concentrated and resuspended in dilute HCl solutions (pH range 1.6
to 6.3) and incubated at either 37u or 60uC, conditions including
those under which insulin forms amyloid fibrils [62,63]. Solutions
were monitored by ThT binding and TEM (Fig. 4). After one week
at 60uC, ThT fluorescence had increased significantly in the pH 5.3
solution (Fig. 4A), which contained a mixture of prefibrillar
aggregates and amyloid fibrils observed by TEM (Fig. 4B–4F)
in both the presence and absence of 0.1% sodium azide. The
fluorescence assays were also performed by diluting protein solutions
into a pH 7.5 buffer since ThT binding may be affected by changes
in pH [67]. In these assays, fluorescence values for the soluble
aggregates were largely unchanged but an increase in intensity for
the pH 5.3 samples was observed (data not shown), consistent with
the lower pH results.
Myostatin fibril formation occurs via a number of stages. For a
3 mg/mL solution, overnight incubation at 60uC in pH 5.3
produces oligomers that are compact and have a ‘bead-on-a-
string’ morphology (Fig. 4B) as observed for Ab and lysozyme
fibrils [60,65]. By three days, extensive arrays of aggregation were
present; these are often three-dimensional, appearing as areas of
high electron density under the TEM (Fig. 4Ci). Increased
elongation and in some places lateral association and longitudinal
fusion of oligomers can be observed (Fig. 4Cii and 4Ciii). This
granular to smooth transition has been shown during Ab fibril
formation [65]. Smaller pore-like oligomers, previously document-
ed on the amyloid formation pathway of a number of proteins
[40,43], are also apparent (Fig. 4Civ and 4Cv). By one week, fibrils
that show the characteristic morphology of amyloid had appeared,
with a diameter of 15.460.7 nm (SD) and a straight, unbranching
structure (Fig. 4D). The fibrils are extremely long, in excess of
5 mm. At two weeks, higher order amyloid structures can be
observed, such as two (Fig. 4E) or more (Fig. 4F) fibrils twisting
around each other.
Secondary Structure Analysis of MstnPP Fibril Formation
by Circular Dichroism Spectroscopy
Amyloid formation is accompanied by the adoption of a b-sheet
rich secondary structure regardless of the structure of the native
protein [68]. Circular dichroism (CD) spectroscopy was used to
study the structural changes that occur during amyloid formation
(Fig. 5). Correctly refolded MstnPP has a CD spectrum indicative
of a mixture of a-helix and b-sheet, in agreement with the crystal
structure of the mature myostatin growth factor [11] and the
mature regions of other TGF-b family members [57]. There are
two minima, the stronger at 218 nm and a second at 208 nm
which are characteristic of b-sheet and a-helical structures
respectively [69]. The absolute negative value at 200 nm implies
a degree of intrinsic disorder exists in the structure [65,70], which
may be functionally significant due to the different roles suggested
for the propeptide region of the myostatin precursor, requiring
flexibility in the N-terminal domain. To our knowledge, this is the
Figure 1. In silico predictions of propensity for b-sheet
aggregation (Tango and PASTA) and amyloid formation
(Waltz). A. MstnPP sequence 21–375 showing regions of elevated
propensity at two levels; red regions have higher propensity than those
in blue. Regions where Waltz, Tango and PASTA predictions overlap are
underlined. The RSRR furin proteolysis sequence that separates the
propeptide from the growth factor domain is shown in bold. B.
Mapping the 348–364 sequence (blue) onto the myostatin growth
factor crystal structure. The region has been shown on one monomer
only.
doi:10.1371/journal.pone.0009170.g001
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first structural analysis for any TGF-b family precursor protein.
Quite a different profile is observed for the MstnPP soluble
aggregates with the very strong minimum at 208 nm indicating
that the secondary structure is primarily a-helical in nature.
Broadening of the spectrum between 215–225 nm may arise from
contributions of b-sheet and a-helix to the spectra. As the CD
spectra of protofibrils of other amyloid-forming proteins is
characterised by b-sheet absorption at 215–218 nm [61,71,72],
it is likely that the MstnPP soluble aggregates represent an
oligomeric intermediate state prior to protofibril formation rather
than protofibrils. Incubation of the aggregates overnight at pH 5.3
and 60uC produces a CD spectrum dominated by b-sheet where
the a-helix minimum at 208 nm is completely replaced by a
minimum at 218 nm. TEM images of the same sample (Fig. 4)
reveals there are no fibrils at this stage but the aggregates are more
compact and have begun to aggregate into large arrays, which
may represent the start of b-sheet stacking as amyloid protofibrils.
The ellipticity for the spectrum is comparatively low, similar to
that observed in the fibrillogenesis of Ab [65]. This reduction of
signal is most likely due to differential absorption flattening, a
phenomenon often seen in the CD spectra of samples containing
suspensions of solid-phase material [61] and causing both a
decrease in intensity and red-shift of all minima. After one week of
incubation the spectrum is similar except for flattening of the
190 nm peak. At this stage, fibrils are present as observed by TEM
analysis of an aliquot of the same sample (Fig. 4). The further
flattening of the spectrum over time is likely to be due to both an
increase in b-sheet structure as well as differential absorption
flattening [61,69]. CD shows that the soluble aggregates differ
dramatically in secondary structure compared to native MstnPP
and that the aggregates may represent an a-helical-containing
intermediate in the transition to protofibrils and fibrils rich in b-
sheet structure.
MstnPP Protofibrils and Fibrils Are Resistant to
Proteolytic Digest by Trypsin
Resistance to proteolytic digestion is another defining charac-
teristic for the presence of amyloid fibrils [73,74]. Comparative
trypsin digestions were performed for the MstnPP fibril-containing
sample, soluble aggregates and native dimer (Fig. 6). Digestion of
the MstnPP dimer and aggregates was carried out with a MstnPP
to trypsin ratio of 100:1 (w/w) at 4uC, room temperature
(approximately 22uC) and 37uC with samples taken after 0.5, 1,
2, 3, 4 and 18 hours. The precursor dimer and aggregates have
comparable trypsin susceptibility at 37uC and are fully digested
after an overnight incubation (18 hours, Fig. 6A and B
respectively). The susceptibility of the soluble aggregates to trypsin
digest suggests an open, flexible structure, consistent with CD
results and supporting the conclusion that this species represents a
prefibrillar intermediate rather than protofibrils. Prior to digestion
the fibril-containing sample is not able to enter the top of the 4%
Figure 2. Refolding and purification of human MstnPP. A. Reducing (+ b-mercaptoethanol (bME)) vs non-reducing (2bME) SDS-PAGE (12%)
after refolding. b-ME concentration is 2 M. Bands are as indicated: 1. soluble aggregates; 2. disulfide-bonded dimer; 3. monomer either fully reduced
(+b-ME) or misfolded at various stages of reduction (2b-ME). Figure assembled from one gel where intervening lanes were removed. B. Heparin
affinity chromatography separates the majority of soluble aggregates (H2) from correctly-folded dimer (H1). C. S200 gel filtration chromatography;
the MstnPP dimer elutes at 13.5 mL (PD) and the soluble aggregates in the void volume at 8 mL (PA).
doi:10.1371/journal.pone.0009170.g002
Myostatin Amyloid Formation
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stacking gel owing to its extremely large size. Following incubation
with trypsin this property is maintained even after overnight
incubation (18 h) at 37uC and a 5-fold increase in trypsin
concentration (MstnPP:trypsin 20:1) (Fig. 6C). Inability to enter
the stacking gel is not a definitive indication of proteolysis
resistance since partial hydrolysis may result in products smaller
than fibrils and/or protofibrils yet still large enough to be retained
in the stacking gel. To address this possibility, TEM analysis
revealed that both MstnPP protofibrils (Fig. 6Di) and mature fibrils
(Fig. 6Dii) had unchanged morphology after trypsin incubation.
MstnPP Aggregates Exhibit Amyloid Characteristics after
Incubation at 37uC
The formation of amyloid fibrils by MstnPP at 60uC and
pH 5.3 is comparable to conditions routinely used to promote
rapid amyloid formation in in vitro model systems for amyloid
diseases. To investigate the temperature range at which structural
changes occur, MstnPP aggregates were analysed by CD from 10
to 65uC immediately after suspension in pH 5.3 (Fig. S3). The
spectrum had changed significantly by 45uC with a loss of a-helix
beginning from 30uC and the appearance of a characteristic
amyloid b-sheet-rich spectrum at 65uC. Subsequently, MstnPP
aggregates were incubated at 37uC at pH 5.3 and monitored with
ThT binding, CD spectroscopy and TEM (Fig. 7). After overnight
incubation ThT binding increased only slightly (Fig. 7A) and CD
indicated that b-sheet aggregation has occurred (Fig. 7B). Under
TEM, the 37uC protofibrils have a similar morphology to the
60uC samples, however aggregation is less extensive (Fig. 7C);
elongation, clustering and ring-like structures are apparent. After
one week of incubation at 37uC, ThT binding increased
significantly (Fig. 7A) and CD showed a definite b-sheet transition
(Fig. 7B). TEM images show increased aggregation, lateral
association and a granular to smooth morphology transition
(Fig. 7D). Although fibril formation did not occur at 37uC in the
time period observed for incubation at 60uC, it is likely that the
kinetics of fibril formation will be slower at the lower temperature.
However, these results show that the properties of protofibrils,
proposed to be direct precursors of mature amyloid fibrils, have
been adopted at 37uC; amyloid formation is likely to occur over an
extended period of time.
MstnPP Aggregates Have a Negative Effect on C2C12
Myoblast Viability
Oligomeric species in the amyloid formation pathway of a
number of proteins are cytotoxic when added to the media of
cultured cells [41,42,65]. The effect of MstnPP soluble aggregates,
Figure 3. Characterisation of MstnPP soluble aggregates by negative-stain transmission electron microscopy (TEM) and ThT
binding. (A–B) TEM of MstnPP soluble aggregates and C. insulin positive control containing both protofibrils (black arrow) and mature fibrils (white
arrow). D. ThT binding of MstnPP soluble aggregates (green), compared to an insulin positive control (red), the MstnPP dimer (yellow) and a buffer
(50 mM Tris-HCl pH 8.5, 150 mM NaCl) blank (blue).
doi:10.1371/journal.pone.0009170.g003
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Figure 4. Characterisation of MstnPP amyloid fibrils by ThT binding and TEM. A. ThT binding after incubation at 60uC and pH 5.3
compared to insulin and MstnPP soluble aggregates. Each result represents the average of four independent experiments and error bars represent
SEM. ** P,0.005 and * P,0.01 by paired Student’s t-test. Blank is 0.005 mM HCl, pH 5.3 and ThT. (B–F) TEM showing different stages in the formation
of prefibrillar structures and fibrils by human MstnPP. B. Overnight incubation at 60uC in pH 5.3 produces ‘beaded’ prefibrillar structures; C. (i) By
three days large, dense three-dimensional arrays show up as areas of high electron density, (ii–v) zoomed in examples of lateral association and
longitudinal fusion (ii and iii) and pore-like structures (iv and v) from (i); D. Characteristic amyloid fibrils after one week; E–F. Formation of higher order
structures with the twisting of two (E) or more (F) fibrils around each other.
doi:10.1371/journal.pone.0009170.g004
Myostatin Amyloid Formation
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protofibrils and fibrils on the viability of C2C12 mouse myoblasts
was investigated by monitoring the absorbance of formazan (Fig. 8)
produced after addition of WST-1 (Roche). Only viable cells
reduce WST-1 to produce formazan with the ratio of absorbances
at 450 and 630 nm correlated to the number of viable cells in the
culture. C2C12 mouse myoblasts are the standard model cell-line
used for the analysis of myostatin activity [16,18]. Although
human MstnPP is used here, sequence identity between the mouse
and human myostatin precursors is 96%; the murine cell-line is
therefore suitable for initial studies. 25 mM of soluble aggregates
and at least 10 mM of protofibrils decreased cell viability
significantly compared to buffer only and correctly folded MstnPP
dimer controls, at the same pH. A solution containing a mixture of
MstnPP protofibrils and fibrils, as well as lower concentrations of
soluble aggregates and protofibrils, had a reduced effect. These
results indicate that oligomeric species in the amyloid formation
pathway of MstnPP affect the normal functioning of C2C12
myoblasts.
Discussion
Amyloid formation is a predominant feature of sIBM [30] with the
Alzheimer’s disease protein Ab associated with sIBM amyloid
structures [31,44]. A role for MstnPP in sIBMwas proposed after co-
localisation and direct association with Ab was observed in diseased
cells [31], and also because ER stress causes an upregulation of
myostatin expression [45]. We now show that a human MstnPP
misfolded species shares the morphological characteristics of amyloid
protofibrils and the ability to bind the amyloid-specific dye thioflavin
T. The a-helical secondary structure of these aggregates suggests
they are most likely to represent an intermediate oligomeric species
that occurs in the transition between native protein and b-sheet-rich
protofibrils. When subjected to the mildly denaturing conditions of
Figure 5. Circular dichroism spectra showing the structural
transitions that occur in amyloid fibril formation. Correctly
folded MstnPP dimer (blue); MstnPP soluble aggregates before
acidification (green); prefibrillar aggregates after overnight incubation
in pH 5.3 at 60uC (red); mixture of prefibrillar aggregates and fibrils after
one week incubation (black).
doi:10.1371/journal.pone.0009170.g005
Figure 6. SDS-PAGE and TEM analysis showing MstnPP resistance to trypsin digestion. A. dimer; and B. soluble aggregates. Major bands
are indicated: 1. MstnPP monomer; 2. MstnPP dimer; 3. MstnPP soluble aggregates. C. MstnPP fibrils: 4. prefibrillar aggregates plus fibrils. Samples
were analysed in sample buffer +/2 bME where bME concentration is 2 M. D. TEM shows resistance of (i) protofibrils and (ii) amyloid fibrils to trypsin.
Trypsin digests were performed with a MstnPP:trypsin ratio of 100:1 (A and B) or 20:1 (C and D) for 18 hours at 37uC.
doi:10.1371/journal.pone.0009170.g006
Myostatin Amyloid Formation
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pH 5.3 and 60uC, the aggregates form amyloid protofibrils and after
one week are able to form long, linear and unbranching amyloid
fibrils. At 37uC, protofibrils and mature fibrils form over an
increased time period. These in vitro results show that MstnPP is
capable of amyloid protofibril and fibril formation, supporting a role
for misfolding of the myostatin precursor in the pathogenesis of
sIBM. MstnPP aggregates and protofibrils have a cytotoxic effect on
mouse myoblasts when added to the culture medium.
CD spectroscopy shows there is a transition from the correctly
folded protein structure to a structure consisting primarily of b-
sheet. For a number of peptides and proteins this transition is from
a loop or disordered region through an a-helical intermediate
stage [36,75]. Analysis of the differently folded forms of MstnPP
suggests a shift towards a predominance of a-helix on misfolding.
Whether this a-helical shift represents the intermediate stage
described for other amyloid species is not known but is an
attractive possibility. TEM images show a number of different
morphological forms present in the aggregate solution. These may
represent different oligomeric intermediates at different stages of
the fibril formation process, some of which may be the direct
precursors of protofibrils. Overnight incubation of MstnPP
aggregates in pH 5.3 at 60uC produces a transition from the a-
helical structure to one dominated by b-sheet. This result is
consistent with the major models proposed for amyloid formation,
which describe an unfolded state in equilibrium with a partly
unfolded a-helix-containing intermediate that accelerates fibril
formation [36,37,76]. Aggregation of the intermediate into
oligomers precedes structural rearrangement into b-sheet-rich
protofibrils. A detailed structure of protofibrils has not been
determined; they are defined primarily by morphology, the ability
to bind dyes such as ThT and a structural shift to a predominance
of b-sheet. Amyloid fibrils have been well-studied structurally by
NMR and X-ray fiber diffraction [77].
For growth factors such as myostatin, and a number of other
secreted proteins, perhaps the biggest obstacle to refolding is the
formation of the correct disulfide-bonded cysteine pairs in the ER
[78]. Myostatin has the characteristic TGF-b cysteine knot motif in
its mature domain [2,10,11] and so likely requires both an
appropriate redox environment and the presence of disulfide-bond
chaperones for correct folding in the ER. The myostatin propeptide
that lies N-terminal to the mature domain has been proposed to
have a chaperone-like function in the correct folding of the mature
domain [8,9]. During ER-stressed situations, such as an altered
redox environment, misfolding can be extensive [48,79] with the
unfolded protein response (UPR) resulting in the elimination of
misfolded proteins and/or apoptosis if necessary [48,80,81]. If the
Figure 7. ThT binding, CD spectroscopy and TEM show the formation of prefibrillar structures and protofibrils by MstnPP
aggregates at 37uC and pH 5.3. A. ThT binding assays before incubation (blue), after overnight incubation (green) and after one week incubation
(red). ***** P,0.001 by Student’s t-test using averaged values over peak. B. CD spectra of MstnPP soluble aggregates (blue), aggregates after
overnight incubation at 37uC in pH 5.3 (green) and after one week incubation (red). C. TEM shows elongation and clustering after overnight
incubation; and D. a granular to smooth transition and enhanced lateral association after one week.
doi:10.1371/journal.pone.0009170.g007
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production of misfolded proteins overwhelms the UPR, protein
aggregation may result in the generation of cytotoxic amyloid
protofibrils [41,42] and mature amyloid fibrils, contributing to
amyloid diseases, including sIBM [32]. After refolding of MstnPP,
misfolded yet soluble aggregates that form amyloid protofibrils and
fibrils at a lowered pH can be observed. Although elevated
temperature has been used to produce mature MstnPP fibrils
quickly in this study, a physiological temperature allows protofibril
and mature fibril formation over an extended time period; by
comparison, fibril formation is expected to occur over many years
in vivo.
sIBM is characterised by amyloid aggregation of the Ab protein
and severe muscle atrophy [30,33]. Previous studies have shown
that MstnPP associates with Ab fibrils in diseased cells [31] and
that ER stress results in upregulation of MstnPP in a cultured
human sIBM-model [45]. Increased activity of the myostatin
growth factor following MstnPP upregulation may contribute to
atrophy in sIBM, however another study showed MstnPP
accumulated with Ab/AbPP within aggresomes following ER
stress by proteasome inhibition in CHMFs [46]. This accumula-
tion in aggresomes may prevent processing of MstnPP and
decrease levels of circulating growth factor, as mature myostatin
growth factor is absent in immunoblots of CHMFs transiently
expressing AbPP [46].
The in vitro formation of MstnPP aggregates and amyloid species
suggests a similar phenomenon could occur in vivo having a
negative effect on cell viability and/or assisting in Ab fibrillogen-
esis. The cytotoxicity exhibited by MstnPP aggregates and
protofibrils in C2C12 cells supports a mechanism in which
aggregation by MstnPP in sIBM contributes to muscle degener-
ation. This may occur independently of atrophy resulting from
increased myostatin growth factor signalling. Even though MstnPP
aggregates were localised to the cytoplasm, aggresomes and
nuclear regions of sIBM tissue in previous studies [31,46], an
absence of extracellular MstnPP was not shown. Since MstnPP is
secreted, possibly for local inhibition of muscle growth [14], post-
secretion aggregation or secretion of aggregated/misfolded
MstnPP may contribute to muscle fiber atrophy in sIBM via a
cytotoxic mechanism that may involve alterations to endo- and
exocytosis [65], alterations to Ca2+ homeostasis and the generation
of reactive oxygen species [41]. The presence of pore-like
structures under TEM suggests that the cytotoxic mechanism
may include permeabilization of extracellular and/or intracellular
membranes [43].
The results presented here show that human MstnPP is able to
form cytotoxic amyloid-like aggregates and amyloid fibrils in vitro,
raising the possibility that amyloid formation by MstnPP in vivo
may contribute to the pathogenesis of sIBM.
Materials and Methods
MstnPP b-Aggregation Propensity by In Silico Analysis
MstnPP amino acids 21–375 were used in b-aggregation
propensity prediction algorithms. Tango [52] and Waltz [55]
output was reproduced from www.tango.embl.de; PASTA output
was taken from www.protein.cribi.unipd.it/pasta [54]. Default
settings were used for all programs.
Expression of Recombinant MstnPP
Full-length human myostatin cDNA was used as a template for
PCR cloning with primers encompassing cDNA corresponding to
human MstnPP amino acid 21 (C-terminal to the signal peptidase
cleavage site) to the C-terminal amino acid 375. PCR fragments
were cloned into a modified pET vector via BamHI and XhoI
restriction sites. Positive colonies were selected by colony PCR.
The pET-MstnPP plasmid was isolated, sequenced and used to
transform E. coli BL21(DE3) cells for protein expression.
Transformed BL21 cells containing pET-MstnPP were grown in
a starter culture of 20 mL LB in the presence of 100 mg/mL
ampicillin (LB amp) at 37uC overnight. The starter culture was
used to inoculate 2 L LB amp and cells were grown at 25uC to an
OD600 of 0.8. Expression was induced by the addition of 0.1 mM
IPTG and cells were incubated overnight (16–18 hours). Cells
were collected by centrifugation at 4,0006g for 30 min at 4uC and
stored at 220uC.
Inclusion Body Isolation and Solubilisation and Refolding
of Recombinant MstnPP
The frozen cell pellet from each 2 L culture was thawed at room
temperature and resuspended in a final volume of 70 mL 20 mM
Tris-HCl pH 8.5. Cells were lysed by two passages through a
French Press at 5,000 psi and the inclusion body pellet was
collected by centrifugation at 30,0006g at 4uC for 30 min. The
inclusion bodies were washed with two 20 mL volumes of wash
buffer (50 mM Tris HCl pH 8.5, 0.5 M NaCl, 10% glycerol,
0.5% Triton-X 100) and two washes with the same volume of
milliQ H2O. Pellets were collected after each wash by centrifu-
gation at 30,0006g for 10 min at 4uC. Solubilisation and refolding
were carried out using methods published previously for the zebra-
fish myostatin precursor protein [8] with some modifications. Each
inclusion body pellet from 2 L of cell culture was solubilised in
8 mL 6 M guanidine hydrochloride (GndHCl), 50 mM Tris-HCl
pH 8.5, 1 mM EDTA, 0.1 mM DTT, at room temperature, with
shaking for 5 hours. Insoluble proteins and cell debris were
removed by centrifugation at 17,0006g, 4uC for 30 min. The
supernatant was acidified to pH ,5.0 by adding a few drops of
concentrated HCl and dialysed overnight against 6 M GndHCl,
50 mM MES pH 5.0, 1 mM EDTA to remove DTT. After
dialysis, the sample was centrifuged again as above. The
solubilised protein (8 mL) was rapidly diluted in 150 mL of freshly
Figure 8. MstnPP aggregates and protofibrils (PF) are cytotoxic
to C2C12 mouse myoblasts. C2C12 cytotoxicity assay using the
WST-1 reagent where the difference in absorbance at 450 and 630 nm
directly correlates to cell density after incubation with increasing
concentrations of MstnPP soluble aggregates (SA, 5–25 mM), protofibrils
(PF, 5–25 mM), 25 mM MstnPP dimer and 25 mM PF/F (fibrils).
Concentrations are expressed as monomer equivalents. Cells incubated
in media containing buffer (B) only (50 mM Tris-HCl pH 8.5, 150 mM
NaCl for soluble aggregates and dimer; 0.005 mM HCl, pH 5.3 for
protofibrils and fibrils) were used as a control. Error bars represent the
standard error of the mean for triplicate samples from two independent
experiments. Statistical significance was calculated using a paired
Student’s t-test where ** P,0.01 and * P,0.05.
doi:10.1371/journal.pone.0009170.g008
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prepared refolding buffer, consisting of 50 mM Tris-HCl pH 8.5,
1 M NaCl, 0.5 M L-arginine, 5 mM EDTA, 5 mM reduced
glutathione and 1 mM oxidised glutathione. The pH was re-
adjusted to 8.5 before addition of protein. The protein was left to
refold without agitation for 6 days at 4uC then centrifuged at
30,0006g, 4uC for 30 min before overnight dialysis into 20 mM
Tris-HCl pH 8.5. Soluble protein was harvested as supernatant
after a second centrifugation and filtered (0.45 mM).
Purification of Refolded MstnPP Dimer and Soluble
Aggregates
Purification of the in vitro refolded MstnPP dimer and misfolded
soluble aggregates was performed by heparin affinity followed by
gel filtration chromatography. The filtered protein solution was
loaded onto a 5 mL HiTrap Heparin HP column (GE Healthcare)
equilibrated with 50 mM Tris-HCl pH 8.5, at a flow rate of
1 mL/min. The flow-through containing unbound protein was
discarded and a stepwise NaCl elution was used to elute the
correctly folded dimer at 200 mM NaCl (H1) and the majority of
soluble aggregates at 600 mM NaCl (H2). Elution was monitored
by absorbance at 280 nm and differently folded forms were
identified using non-reduced SDS-PAGE. Further purification of
the MstnPP dimer was achieved using gel filtration chromatog-
raphy. The 200 mM NaCl peak was filtered (0.22 mM), concen-
trated to 350 mL and applied to a Superdex S200 10/300 HR
column (GE Healthcare) equilibrated with 50 mM Tris-HCl,
pH 8.5, 150 mM NaCl, at a flow rate of 0.5 mL/min. The dimer
eluted at approximately 13.5 mL (PD) and was separated from any
remaining soluble aggregates that eluted in the void volume (PA).
Western Blotting
Protein samples were separated on a 12% SDS-PAGE gel at
150 V and transferred to a nitrocellulose membrane overnight at
15 V (approximately 40–150 mA) in cooled Tris/glycine transfer
buffer. The next day transfer of high molecular weight samples
was ensured at 450 mA for one hour. Efficient transfer was
confirmed by Ponceau S staining. Membranes were blocked with
5% non-fat milk in TBS-Tween (TBS-T; 20 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 0.1% Tween-20) for one hour at room
temperature and subsequently incubated in rabbit anti-myostatin
polyclonal primary antibody (Chemicon International), diluted
1/10,000 in 1% non-fat milk TBS-T, for 90 minutes. Following
washing with TBS-T, membranes were incubated in a 1/50,000
dilution (1% non-fat milk, TBS-T) of horse radish peroxidase-
conjugated anti-rabbit antibody (Jackson ImmunoResearch) for 90
minutes. All steps were performed at room temperature. After
washing with TBS-T, proteins were visualised with the Super-
Signal West Pico Chemiluminescent Substrate (Pierce) according
to manufacturer’s instructions.
Generation of MstnPP Amyloid Fibrils
MstnPP soluble aggregates were sterile-filtered (0.22 mm),
concentrated 10-fold and resuspended in dilute HCl solutions at
a final concentration of 1 mg/mL, as measured by both Bradford
assay and absorbance at 280 nm. Initially, a range of pH solutions
were investigated for fibril formation from pH 1.6, as used for
insulin amyloid formation [63] through to pH 6.3. Samples were
placed at either 37uC or 60uC and monitored frequently for
amyloid formation by Thioflavin T (ThT) fluorescence, TEM and
CD spectroscopy. Subsequent to this optimisation, MstnPP
aggregates were incubated at pH 5.3 (0.005 mM HCl) and 60uC
for at least one week. Identical MstnPP amyloid fibrils were
formed in equivalent solutions containing 0.1% sodium azide.
Generation of Insulin Protofibrils and Fibrils
Insulin protofibrils and fibrils were produced as described [63].
In brief, different concentrations of insulin (bovine pancreas,
Sigma) ranging from 0.5–2 mg/mL (85–340 mM) were prepared
in 25 mM HCl (pH 1.6) and placed at 60uC for an hour
(protofibrils) or at least overnight (fibrils) although incubation times
were dependent on protein concentration.
Negative-Stained Transmission Electron Microscopy
Dimer and aggregate samples direct from purification (heparin
affinity or gel filtration) were buffer-exchanged into water.
Amyloid solutions were used directly in dilute HCl. 200-mesh
carbon-coated Formvar grids were placed on 30 mL protein
solution (0.5 mg/mL) droplets for 45 seconds. Excess sample was
drawn off using filter paper and the grids were placed on an equal
volume of 2% uranyl acetate for 45 seconds. Excess stain was
drawn off as above and the grids were air-dried briefly before
viewing with a Philips CM10 transmission electron microscope.
Fibril measurement and statistical analysis was performed using
iTEM software (Olympus) with a sample size of 10 fibrils from the
same grid.
Thioflavin T Binding Assays
A solution of Thioflavin T (Sigma) was prepared at 400 uM in
water [64] then diluted directly into the protein solution giving a
final concentration of 20 mM per assay (as done previously for
insulin [63]). A final protein concentration of 1 mg/mL was used
for all samples. Experiments at pH 7.5 were performed after
diluting both protein and ThT into 50 mM Tris-HCl pH 7.5,
100 mM NaCl. Fluorescence assays were conducted with the
Perkin Elmer LS50B Luminescence Spectrometer with excitation
at 450 nm and the emission spectrum measured from 460–
530 nm. Error bars are standard errors for four independent
measurements. The Student’s t-test was performed using Graph-
Pad Prism (GraphPad Software, Inc).
Circular Dichroism Spectroscopy
CD spectra in the far-UV region (180–260 nm) were obtained
on a Chirascan CD spectrometer (Applied Biophysics) using a
0.1 mm path cell and protein concentrations of 1 mg/mL at 4uC.
For all samples, 20 runs were performed with 1 nm readings taken
every 2.5 seconds, followed by smoothing and baseline subtraction.
For CD thermal denaturation, 1 nm/2.5 second readings were
taken at every 5uC increase in temperature from 10–65uC with a
30 second equilibration time at each temperature and a tolerance
level of 0.2uC.
Protease Resistance Analysis
MstnPP samples were tested for protease resistance using a
myostatin to trypsin (bovine pancreas, Sigma) ratio of 100:1 or
20:1 (w/w). 100:1 solutions were incubated at 4uC, room
temperature or 37uC. Samples were taken at 0.5, 1, 2, 3, 4 and
18 hours (overnight), immediately denatured to end the reaction
and analysed by reducing and non-reducing SDS-PAGE. For
subsequent protease resistance analysis of MstnPP amyloid fibrils,
the myostatin to trypsin ratio was 20:1 (w/w) with incubation at
37uC for 4 and 18 hours and analysis by SDS-PAGE and TEM.
Cell Culture and Incubation with Protein Aggregates
C2C12 mouse myoblasts were cultured in Advanced Dulbecco’s
Modified Eagle’s Medium (Gibco, Invitrogen) containing 4.5 g/L
D-glucose and 110 mg/L sodium pyruvate and supplemented
with 10% foetal calf serum, 4 mM L-glutamine and penicillin/
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streptomycin. Cells were incubated in a 5% CO2 humidified
environment at 37uC. Cells were plated in fresh medium in optical
bottom 96-well plates (Nunc) at a density of 2,500 cells/well for
cytotoxicity assays. After 24 hours, media was removed and
100 mL/well fresh medium containing protein was added. Two
independent experiments with triplicate wells were used for each
condition. Cells incubated in media containing buffer (B) only
(50 mM Tris-HCl pH 8.5, 150 mM NaCl for soluble aggregates
and dimer; 0.005 mM HCl, pH 5.3 for protofibrils and fibrils)
were used as a control. Concentrations of myostatin samples used
in the assay were comparable to those from previous protein fibril
studies [41,42,65].
WST-1 Colorimetric Assay for Cytotoxicity
The WST-1 reagent (Roche) is a tetrazolium-based salt that can
be metabolized by viable cells only to produce a water-soluble
formazan product measurable in a colorimetric assay. After a 24-
hour incubation with protein, 10 mL WST-1 was added to each
well and the plate was incubated for a further 3 hours. Absorbance
at 450 nm was measured in a PowerWave XS 96-well plate reader
(BioTek Instruments, Inc) with 630 nm readings taken as
reference. Phenol red-free media was not used as the indicator
does not interfere with the WST-1 assay; as phenol red absorbs
slightly at 450 nm however, wells containing media only were used
as an additional control [82].
Supporting Information
Figure S1 In silico predictions of propensity for b-sheet
aggregation (A and B) and regions responsible for amyloid
formation (C) by MstnPP. (A) Tango; (B) PASTA; and (C) Waltz.
The MstnPP amino acid sequence from residues 21–375 were
used for the calculations at a theoretical pH of 7. Default settings
were used for all algorithms.
Found at: doi:10.1371/journal.pone.0009170.s001 (0.24 MB
DOC)
Figure S2 Western blot and SDS-PAGE of MstnPP purification
procedure. (A) 12% reducing (+ bME) vs non-reducing (2 bME)
SDS-PAGE and (B) subsequent Western blot of purification
procedure. Lanes are as follows: H1, heparin peak 1; H2, heparin
peak 2; PD, gel filtration purified dimer; PA, gel filtration purified
aggregates. Major bands are indicated: 1. soluble aggregates; 2.
dimer; 3. monomer. b-ME concentration in + b-ME lanes is 2 M.
Found at: doi:10.1371/journal.pone.0009170.s002 (1.42 MB
DOC)
Figure S3 CD thermal denaturation of MstnPP soluble
aggregates at pH 5.3 shows a gradual transition from an a-helical
dominated spectrum at 10uC to one rich in b-sheet at 65uC.
Significant loss of the a-helical minimum begins at 40uC.
Found at: doi:10.1371/journal.pone.0009170.s003 (0.21 MB
DOC)
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